ArticleBiology of reproduction2025
A mouse model engineered to spatiotemporally control Cre expression in progesterone receptor positive cells†.
Article in Biology of reproduction, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- FTO Controls Endometrial Receptivity and Embryo Implantation through Regulating mCommunications biology · 2026Article
- Deciphering the maternal uterine signals that shape placenta development.Reproduction (Cambridge, England) · 2026Review
- The progesterone receptor's journey through mouse models.Nature reviews. Endocrinology · 2026Article
- Impact of vitamin D deficiency on defective endometrial decidualization and the repressive role of vitamin D receptor (VDR) in the epigenomic network.bioRxiv : the preprint server for biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The Cre/loxP system is widely used for site-specific genetic manipulation in mice. The PgrCre mouse model, where Cre recombinase is driven by the progesterone receptor promoter, is commonly used for gene ablation in Pgr-positive uterine cells. However, the PgrCre is active in the neonatal uterus and does not allow temporal control. To enhance the functionality of the PgrCre mouse, we generated and characterized an inducible PgriCreERT2 mouse, in which iCreERT2 is inserted downstream of the endogenous Pgr promoter. PgriCreERT2 mice crossed with Rosa26-CAG-LSL-Sun1-sfGFP-myc reporter mice demonstrated tamoxifen-dependent recombination in uterine stromal fibroblasts and a subset of epithelial cells. Tamoxifen-induced ablation of PGR expression was accomplished by crossing PgriCreERT2 mice with the Pgrflox/flox mice. Resulting PgriCreERT2/Pgr:flox and Pgrflox/flox mice were treated with tamoxifen or oil vehicle daily for 3 days and assayed for fertility 1 month after treatment. Tamoxifen-treated PgriCreERT2/Pgr:flox mice exhibited implantation failure, dysregulation of uterine epithelial and stromal cell proliferation, and loss of decidualization response with no impact on ovulation or embryo transport. A 6-month breading trial demonstrated that 4/6 tamoxifen-treated PgriCreERT2/Pgr:flox mice were completely infertile, and the remaining 2/6 delivered only three total pups each near the end of the trial. In contrast, tamoxifen-treated Cre-negative females were fertile with normal uterine receptivity compared to vehicle controls, indicating that tamoxifen administration with a month-long recovery period did not impair pregnancy. Together, these data demonstrate the utility of this inducible PgriCreERT2 mouse model for spatiotemporally controlled gene ablation in Pgr-positive cells of the uterus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.